Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of oliceridine with propofol for suppressing intubation response during rigid bronchoscopy in elderly lung cancer patients
ChiCTR2500109653Phase 4Completed
- Sponsor
- Xianyang Central Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oliceridine in bronchial carcinoma, sponsored by Xianyang Central Hospital. Primary endpoints: ED50 of oliceridine for inhibiting rigid bronchoscopy intubation response and ED95 of oliceridine for inhibiting rigid bronchoscopy intubation response. Started Sep 2025; status: completed.
02
Drugs
oliceridine
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2500109653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109653.